DAMORA THERAPEUTICS, INC. Earnings Per Share, Basic and Diluted
DAMORA THERAPEUTICS, INC. (DMRA) reported Earnings Per Share, Basic and Diluted of -$0.67 per share for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-07-29.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-07-29
- DAMORA THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2022-06-30 was -$0.67.
- DAMORA THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.67.
- DAMORA THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.50.
- DAMORA THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.49.
- DAMORA THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2021 was -$2.05.
- DAMORA THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2020 was -$7.62.
- DAMORA THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2019 was -$161.82.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$0.67 10-Q · filed 2022-07-29 | -$1.34 10-Q · filed 2022-07-29 | ||
| 2022-03-31 | -$0.67 10-Q · filed 2022-04-29 | |||
| 2021-12-31 | -$2.05 10-K · filed 2022-02-17 | |||
| 2021-09-30 | -$0.50 10-Q · filed 2021-11-04 | -$1.52 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | -$0.49 10-Q · filed 2022-07-29 | -$1.02 10-Q · filed 2022-07-29 | ||
| 2021-03-31 | -$0.53 10-Q · filed 2022-04-29 | |||
| 2020-12-31 | -$0.22 derived: net income ÷ weighted average shares · filed 2022-02-17 | -$2.06 derived: net income ÷ weighted average shares · filed 2022-02-17 | -$7.62 10-K · filed 2022-02-17 | |
| 2020-09-30 | -$55.25 10-Q · filed 2021-11-04 | -$118.89 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | -$22.83 10-Q · filed 2021-08-05 | -$44.66 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$21.83 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | -$99.34 derived: net income ÷ weighted average shares · filed 2021-03-29 | -$120.52 derived: net income ÷ weighted average shares · filed 2021-03-29 | -$161.82 10-K · filed 2021-03-29 | |
| 2019-09-30 | -$21.18 10-Q · filed 2020-12-11 | -$62.48 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |